Sign up Australia
Proactive Investors - Run By Investors For Investors

Living Cell Technologies maps timeline to clinical results from Parkinson's trial

The halt will remain in place until Monday 13th November 2017.
Living Cell Technologies maps timeline to clinical results from Parkinson's trial
The company's shares are in pre-open

Living Cell Technologies Ltd (ASX:LCT) is preparing some highly anticipated results from the NTCELL Parkinson's disease clinical trial, which are expected on Friday 10th November 2017.

Shares in the company had been rising on the anticipation, recently hitting $0.28, but have lost some momentum and were changing hands at $0.205 at yesterday's close.

Mid-year shares could have been snapped up around the $0.11 range.

The ASX has this morning granted Living Cell a trading halt to prepare details from the trial.

The halt will remain in place until the opening of trade on Monday 13th November 2017, or earlier if an announcement is made to the market.

View full LCT profile View Profile

Living Cell Technologies Ltd Timeline

Related Articles

Regeneus: Access latest PPT from Proactive's CEO Sessions
June 19 2017
John Martin discussed regenerative medicine with investors.
e-Therapeutics
August 17 2017
E-Therapeutics’ network-driven drug discovery platform looks at the broader interactions within disease mechanisms
1518096073_biotechLatest.jpg
February 09 2018
The subsector in which Abezena is active in (monoclonal antibody and conjugated monoclonal antibodies) could expand to US$180bn, Peel Hunt’s research suggests

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use